A Study to Assess the Pharmacokinetics of Midazolam, Dabigatran, Pitavastatin, Atorvastatin, and Rosuvastatin Administered as Microdoses in Subjects With Varying Degrees of Renal Insufficiency in the Presence and Absence of Rifampin
Phase of Trial: Phase I
Latest Information Update: 20 Aug 2018
Price : $35 *
At a glance
- Drugs Atorvastatin (Primary) ; Dabigatran etexilate (Primary) ; Midazolam (Primary) ; Pitavastatin (Primary) ; Rifampicin (Primary) ; Rosuvastatin (Primary)
- Indications Dyslipidaemias; Hypercholesterolaemia; Hyperlipidaemia; Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 08 Aug 2018 Status changed from active, no longer recruiting to completed.
- 11 Jun 2018 Status changed from recruiting to active, no longer recruiting.
- 16 Mar 2018 Planned primary completion date changed from 19 Jul 2018 to 30 Jul 2018.